Charlene S Dezzutti

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. doi request reprint Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention
    Charlene S Dezzutti
    University of Pittsburgh, 204 Craft Avenue, Pittsburgh, Pennsylvania, 15213, USA
    Pharm Res 32:3768-81. 2015
  2. pmc Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities
    Charlene S Dezzutti
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Magee Womens Research Institute, 204 Craft Avenue, Rm 503B, Pittsburgh, PA 15213, USA
    Curr HIV/AIDS Rep 10:12-20. 2013
  3. pmc Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity
    Charlene S Dezzutti
    Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 7:e48328. 2012
  4. pmc Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial
    Charlene S Dezzutti
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Magee Womens Research Institute, Pennsylvania 15213, USA
    J Infect Dis 206:1931-5. 2012
  5. pmc Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention
    Charlene S Dezzutti
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Antiviral Res 96:221-5. 2012
  6. pmc Reformulated tenofovir gel for use as a dual compartment microbicide
    Charlene S Dezzutti
    University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Antimicrob Chemother 67:2139-42. 2012
  7. pmc Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators
    Charlene S Dezzutti
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 6:e23136. 2011
  8. pmc In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide
    Lisa C Rohan
    Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 5:e9310. 2010
  9. pmc Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model
    Marilyn Cost
    Magee Womens Research Institute, Pittsburgh, Pennsylvania, USA
    Antimicrob Agents Chemother 56:3058-66. 2012
  10. pmc Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1
    Betsy C Herold
    Departments of Pediatrics and Microbiology Immunology, Albert Einstein College of Medicine, Yeshiva University, New York, NY University of Pittsburgh, Pittsburgh, PA Magee Womens Research Institute, Pittsburgh, PA University of Washington, Seattle, WA Fred Hutchinson Cancer Research Center, Seattle, WA and Johns Hopkins University, Baltimore, MD
    J Acquir Immune Defic Syndr 66:65-73. 2014

Collaborators

Detail Information

Publications21

  1. doi request reprint Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention
    Charlene S Dezzutti
    University of Pittsburgh, 204 Craft Avenue, Pittsburgh, Pennsylvania, 15213, USA
    Pharm Res 32:3768-81. 2015
    ..Dapivirine (DPV), a non-nucleoside reverse transcriptase inhibitor, and maraviroc (MVC), a CCR5 antagonist, were formulated into aqueous gels designed to prevent mucosal HIV transmission...
  2. pmc Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities
    Charlene S Dezzutti
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Magee Womens Research Institute, 204 Craft Avenue, Rm 503B, Pittsburgh, PA 15213, USA
    Curr HIV/AIDS Rep 10:12-20. 2013
    ..This review will discuss the use of mucosal tissue to better understand HIV-1 pathogenesis and prevention modalities...
  3. pmc Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity
    Charlene S Dezzutti
    Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 7:e48328. 2012
    ..The two iso-osmolar lubricants, Good Clean Love and PRÉ, and both silicone-based lubricants, Female Condom 2 lubricant and Wet Platinum, were the safest in our testing algorithm...
  4. pmc Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial
    Charlene S Dezzutti
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Magee Womens Research Institute, Pennsylvania 15213, USA
    J Infect Dis 206:1931-5. 2012
    ..22; P = .01) prior to seroconversion. E. coli bactericidal activity remained significant in a multivariable analysis (P = .02) and may be a biomarker for HIV-1 acquisition...
  5. pmc Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention
    Charlene S Dezzutti
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Antiviral Res 96:221-5. 2012
    ..The safety and efficacy profiles of the gels were similar for ectocervical and colorectal tissues suggesting these gels have the potential for dual compartment use...
  6. pmc Reformulated tenofovir gel for use as a dual compartment microbicide
    Charlene S Dezzutti
    University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Antimicrob Chemother 67:2139-42. 2012
    ..This study evaluated the pre-clinical safety and efficacy of a reformulated (reduced osmolality) tenofovir gel product...
  7. pmc Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators
    Charlene S Dezzutti
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 6:e23136. 2011
    ..However, optimal methods for sample collection do not exist. This study compared collection methods...
  8. pmc In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide
    Lisa C Rohan
    Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 5:e9310. 2010
    ..To validate our findings with on-going clinical trial results, we evaluated topical tenofovir gel for safety and efficacy. We also modeled systemic application of tenofovir for efficacy...
  9. pmc Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model
    Marilyn Cost
    Magee Womens Research Institute, Pittsburgh, Pennsylvania, USA
    Antimicrob Agents Chemother 56:3058-66. 2012
    ..This study successfully demonstrates the feasibility of using this novel combination of antiretroviral agents in an aqueous gel as an HIV infection preventative...
  10. pmc Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1
    Betsy C Herold
    Departments of Pediatrics and Microbiology Immunology, Albert Einstein College of Medicine, Yeshiva University, New York, NY University of Pittsburgh, Pittsburgh, PA Magee Womens Research Institute, Pittsburgh, PA University of Washington, Seattle, WA Fred Hutchinson Cancer Research Center, Seattle, WA and Johns Hopkins University, Baltimore, MD
    J Acquir Immune Defic Syndr 66:65-73. 2014
    ..We measured CVL antiviral activity in women using oral or vaginal tenofovir-based pre-exposure prophylaxis and correlated activity with drug and immune mediator levels...
  11. pmc Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention
    Ayman Akil
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA
    Pharm Res 32:458-68. 2015
    ..To develop polymeric films containing dual combinations of anti-HIV drug candidate tenofovir, maraviroc and dapivirine for vaginal application as topical microbicides...
  12. ncbi request reprint Preventing the sexual transmission of HIV-1 with topical microbicides: another piece of the equation
    Lisa C Rohan
    Department of Pharmaceutical Science, School of Pharmacy, University of Pittsburgh, PA, USA
    J Infect Dis 196:1285-7. 2007
  13. pmc Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation
    Charlene S Dezzutti
    Magee Womens Research Institute, Pittsburgh, Pennsylvania, United States of America Department Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 9:e102585. 2014
    ..Our in vitro and ex vivo results show successful formulation of unique RMs. Moreover, the results of flex sig and surgically resected tissues were comparable suggesting the incorporation of both in pre-clinical testing algorithms. ..
  14. pmc Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles
    Anthony S Ham
    Magee Womens Research Institute, 204 Craft Avenue, B509, Pittsburgh, Pennsylvania, 15213, USA
    Pharm Res 26:502-11. 2009
    ..Nanoparticles formulated from the biodegradable co-polymer poly(lactic-co-glycolic acid) (PLGA), were investigated as a drug delivery system to enhance tissue uptake, permeation, and targeting for PSC-RANTES anti-HIV-1 activity...
  15. doi request reprint Assessing the potential of the Woman's Condom for vaginal drug delivery
    Lindsay F Kramzer
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, 3501 Terrace Street, Pittsburgh, PA, 15261, USA Magee Womens Research Institute, 204 Craft Avenue, Pittsburgh, PA, 15213, USA
    Contraception 92:254-60. 2015
    ..This preclinical study assessed the feasibility to incorporate an antiviral drug, UC781, into the Woman's Condom capsule, offering a unique drug delivery platform...
  16. doi request reprint Vaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission
    Wei Zhang
    Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, USA
    Pharm Res 32:2960-72. 2015
    ..The objective of this study was to develop and characterize film-formulated EFdA and CSIC for use as a female-controlled vaginal microbicide to prevent sexual transmission of HIV...
  17. pmc The effect of menopause on the innate antiviral activity of cervicovaginal lavage
    Catherine A Chappell
    Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA Electronic address
    Am J Obstet Gynecol 213:204.e1-6. 2015
    ..Our objectives were to determine the effect of hormonal status on intrinsic antiviral (herpes simplex virus [HSV]-1, HSV-2, and human immunodeficiency virus [HIV]-1) activity of cervicovaginal lavage (CVL)...
  18. pmc Y chromosome and HIV DNA detection in vaginal swabs as biomarkers of semen and HIV exposure in women
    Kerri J Penrose
    From the University of Pittsburgh, Pittsburgh, PA University of Washington, Seattle, WA Magee Womens Research Institute, Pittsburgh, PA Albert Einstein College of Medicine, New York, NY and Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
    Sex Transm Dis 41:674-9. 2014
    ..We investigated the detection of HIV-1 and Y chromosomal (Yc) DNA in vaginal swabs from 83 participants in the HPTN 035 microbicide trial as biomarkers of HIV exposure and unprotected sexual activity...
  19. pmc HIV-1 infection of female genital tract tissue for use in prevention studies
    Charlene S Dezzutti
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA Alpha StatConsult, LLC, Damascus, MD and University of Pittsburgh Medical Center, Pittsburgh, PA
    J Acquir Immune Defic Syndr 63:548-54. 2013
    ..Ex vivo HIV-1 challenge has been proposed as a bioindicator of microbicide product effectiveness. The objective of this study was to establish optimal parameters for use of female genital tract tissue in this model...
  20. pmc Effect of topical microbicides on infectious human immunodeficiency virus type 1 binding to epithelial cells
    Susan Roth
    University of Pittsburgh, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee Womens Research Institute, 204 Craft Avenue, Pittsburgh, PA 15213, USA
    Antimicrob Agents Chemother 51:1972-8. 2007
    ..Therefore, functional virological assays in addition to measuring viral RNA should be included when clinically evaluating topical microbicide use by infected persons...
  21. doi request reprint Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial
    Beatrice A Chen
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA Magee Womens Research Institute, Pittsburgh, PA Department of Medicine and Infectious Disease, Fenway Institute, Boston, MA Department of Pathology and Medicine, Johns Hopkins University, Baltimore, MD Department of Medicine, University of Alabama at Birmingham, Birmingham, AL Women s Global Health Imperative WGHI RTI International, San Francisco, CA Center for AIDS Prevention Studies, University of California San Francisco, Department of Medicine, San Francisco, CA Statistical Center for HIV AIDS Research and Prevention Fred Hutchinson Cancer Research Center, Seattle, WA NIAID DAIDS, Bethesda, MD International Partnership for Microbicides, Silver Spring, MD FHI 360, Durham, NC and Alpha StatConsult, Damascus, MD
    J Acquir Immune Defic Syndr 70:242-9. 2015
    ..Variable adherence limits effectiveness of daily oral and intravaginal tenofovir-containing pre-exposure prophylaxis. Monthly vaginal antiretroviral rings are one approach to improve adherence and drug delivery...